Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05324449 · ClinicalTrials.gov registry record · Phase 4
Epidiolex® for Anxiety in Pediatric Epilepsy
A Phase 4 study of Anxiety and Epilepsy, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05324449: Completed Phase 4 study of Anxiety and Epilepsy, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
NCT05324449 is a Phase 4 study of Anxiety and Epilepsy that has completed, run by Hugo W. Moser Research Institute at Kennedy Krieger. The registered enrollment target is 20 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05324449, a Phase 4 study of Anxiety and Epilepsy, has completed, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective open label study assessing the efficacy and tolerability of pharmaceutical grade cannabidiol--Epidiolex (R), for the treatment of anxiety in pediatric patients with pediatric epilepsy that has been difficult to treat and requires ongoing use of anticonvulsant medication.
Primary Outcome
Mean of Clinical Global Impression-Improvement (CGI-I) from baseline. The CGI is rated on a 7-point scale. (lower score represents a better outcome: 1/ High score represents minimum improvement: 7)
Interventions
- DRUG Cannabidiol 100 MG/ML
Study Locations (1)
Maryland
- Kennedy Krieger Institute - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-04-05 |
| Est. Completion | 2025-05-05 |
| Phase | Phase 4 |
What the finished NCT05324449 record still lists
NCT05324449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 1 intervention - of which Cannabidiol 100 MG/ML is the first listed.
NCT05324449 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05324449 about?
NCT05324449 is a clinical study titled "Epidiolex® for Anxiety in Pediatric Epilepsy". This is a prospective open label study assessing the efficacy and tolerability of pharmaceutical grade cannabidiol--Epidiolex (R), for the treatment of anxiety in pediatric patients with pediatric epilepsy that has been difficult to treat and requires ongoing use of anticonvulsant medication.
What is the current status of trial NCT05324449?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2022-04-05. Estimated completion is 2025-05-05.
What conditions does trial NCT05324449 study?
This clinical trial studies the following conditions: Anxiety, Epilepsy.
What interventions are being tested in trial NCT05324449?
The interventions under investigation include: Cannabidiol 100 MG/ML (DRUG).
Who is sponsoring clinical trial NCT05324449?
This trial is sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05324449 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05324449's enrollment target sits among peer trials
20 326th of 364 higher than 34 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
-
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
RECRUITING · Phase 4
-
IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED
RECRUITING · Phase 4
-
Brain Stimulation & Generalized Anxiety Study
ACTIVE NOT RECRUITING · Phase 4
-
Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting
COMPLETED · Phase 4
-
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI